J. David Gladstone Institutes
| |
Award Total: $7,224,186 |
# of Awards: 17 |
Home Page: |
Investigators
| |
Martin Bergo , M.D., Ph.D. -
Martin Bergo , M.D., Ph.D. -
Johan Bjorkegren , M.D., Ph.D. -
David Dichek , M.D. -
Martin Hersberger , Ph.D. -
Ugur Hodoglugil , M.D., Ph.D. -
Yadong Huang , M.D., Ph.D. -
Thomas Innerarity , Ph.D. -
Thomas Innerarity , Ph.D. -
Beatriz Levy-Wilson , Ph.D. -
Robert Pitas , Ph.D. -
Robert Pitas , Ph.D. -
Robert Pitas , Ph.D. -
Robert Pitas , Ph.D. -
Robert Raffai , Ph.D. -
Murielle Marie Veniant , Ph.D. -
Stephen Young , M.D. -
Stephen Young , M.D. -
|
Grants
| |
Title |
Cycle [sort] |
Award |
| |
A model system for smoking-related damage to proteins |
1999 (Cycle VIII) |
$75,375 |
| |
Investigator(s): Johan Bjorkegren , M.D., Ph.D. |
8FT-0022 |
| |
ApoE isoforms, fatty acid metabolism and atherosclerosis |
2001 (Cycle X) |
$691,616 |
| |
Investigator(s): Robert Pitas , Ph.D. |
10RT-0313 |
| |
Apolipoprotein E: remnant metabolism and atherogenesis |
1999 (Cycle VIII) |
$793,474 |
| |
Investigator(s): Yadong Huang , M.D., Ph.D. |
8RT-0130 |
| |
Cloning & Expression of the Apo-B mRNA Editing Factor |
1994 (Cycle III) |
$254,743 |
| |
Investigator(s): Thomas Innerarity , Ph.D. |
3RT-0404 |
| |
Determining how cholesterol-rich Lp(a) causes heart disease |
1998 (Cycle VII) |
$797,092 |
| |
Investigator(s): Robert Pitas , Ph.D. |
7RT-0018 |
| |
Enzymatic targets for anticancer therapy |
2002 (Cycle XI) |
$267,304 |
| |
Investigator(s): Martin Bergo , M.D., Ph.D. |
11KT-0087 |
| |
Expression of the Human apo-B Gene in Transgenic Mice |
1995 (Cycle IV) |
$211,090 |
| |
Investigator(s): Beatriz Levy-Wilson , Ph.D. |
4RT-0308 |
| |
How are beneficial cholesterol transport proteins produced? |
1998 (Cycle VII) |
$37,069 |
| |
Investigator(s): Martin Hersberger , Ph.D. |
7FT-0005 |
| |
How does cardiac fuel metabolism influence heart disease? |
1998 (Cycle VII) |
$262,005 |
| |
Investigator(s): Murielle Marie Veniant , Ph.D. |
7KT-0020 |
| |
Importance of Rce1 and Ras in tobacco-induced cancers |
1999 (Cycle VIII) |
$75,209 |
| |
Investigator(s): Martin Bergo , M.D., Ph.D. |
8FT-0137 |
| |
Lipoprotein classes and susceptibility to atherosclerosis |
1998 (Cycle VII) |
$702,940 |
| |
Investigator(s): Stephen Young , M.D. |
7RT-0032 |
| |
Post-isoprenylation processing steps as anticancer targets |
2000 (Cycle IX) |
$1,017,450 |
| |
Investigator(s): Stephen Young , M.D. |
9RT-0243 |
| |
Proteins that Remove Atherogeneic Lipoproteins from Blood |
1995 (Cycle IV) |
$678,254 |
| |
Investigator(s): Robert Pitas , Ph.D. |
4RT-0282 |
| |
Remnant lipoproteins, apolipoprotein E4 and atherosclerosis |
2001 (Cycle X) |
$400,500 |
| |
Investigator(s): Robert Raffai , Ph.D. |
10KT-0318 |
| |
Towards gene therapy for tobacco-related vascular disease |
1998 (Cycle VII) |
$719,328 |
| |
Investigator(s): David Dichek , M.D. |
7RT-0016 |
| |
Triglyceride metabolism: Genetics, smoking and heart disease |
2003 (Cycle XII) |
$75,438 |
| |
Investigator(s): Ugur Hodoglugil , M.D., Ph.D. |
12FT-0226 |
| |
Will ApoE cause regression of atherosclerotic lesions? |
1998 (Cycle VII) |
$165,299 |
| |
Investigator(s): Robert Pitas , Ph.D. |
7RT-0009 |
|
